Skip to main content

Reasons To Own Regeneron In 2017; CS Sees 30% Upside

It looks like 2017 will be a big year for Regeneron ( REGN ). Credit Suisse upgraded the stock a market perform to an outperform and sees the share price climbing 30% over the next year to $485. And a big part of that bullish argument revolves around the anticipated 2017 launch of the eczema drug Dupixent. Now awaiting FDA approval, the drug is widely expected to be the company’s next big blockbuster. But Credit Suisse analyst Alethia Young and her team of analysts see several other catalysts --more catalysts than risks -- ahead in 2017. In fact, she says there are five major events to watch for next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.